BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017;377:1824-35. [PMID: 28891423 DOI: 10.1056/NEJMoa1709030] [Cited by in Crossref: 1023] [Cited by in F6Publishing: 394] [Article Influence: 255.8] [Reference Citation Analysis]
Number Citing Articles
1 Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol 2018;36:3441-9. [PMID: 30343620 DOI: 10.1200/JCO.18.01219] [Cited by in Crossref: 124] [Cited by in F6Publishing: 41] [Article Influence: 41.3] [Reference Citation Analysis]
2 Mundra PA, Dhomen N, Rodrigues M, Mikkelsen LH, Cassoux N, Brooks K, Valpione S, Reis-Filho JS, Heegaard S, Stern MH, Roman-Roman S, Marais R. Ultraviolet radiation drives mutations in a subset of mucosal melanomas. Nat Commun 2021;12:259. [PMID: 33431815 DOI: 10.1038/s41467-020-20432-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Prodam F, Caputo M, Mele C, Marzullo P, Aimaretti G. Insights into non-classic and emerging causes of hypopituitarism. Nat Rev Endocrinol 2021;17:114-29. [PMID: 33247226 DOI: 10.1038/s41574-020-00437-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ryan AL, Burns C, Gupta AK, Samarasekera R, Ziegler DS, Kirby ML, Alvaro F, Downie P, Laughton SJ, Cross S, Hassall T, McCowage GB, Hansford JR, Kotecha RS, Gottardo NG. Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children's Oncology Group (ANZCHOG) Study. Front Oncol 2021;11:660172. [PMID: 33996584 DOI: 10.3389/fonc.2021.660172] [Reference Citation Analysis]
5 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 2020;9:1722023. [PMID: 32076579 DOI: 10.1080/2162402X.2020.1722023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
7 Wright FC, Souter LH, Kellett S, Easson A, Murray C, Toye J, McCready D, Nessim C, Ghazarian D, Hong NJL, Johnson S, Goldstein DP, Petrella T; Melanoma Disease Site Group. Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline. Curr Oncol 2019;26:e541-50. [PMID: 31548823 DOI: 10.3747/co.26.4885] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
8 Patel A, Carr MJ, Sun J, Zager JS. In-transit metastatic cutaneous melanoma: current management and future directions. Clin Exp Metastasis 2021. [PMID: 33999365 DOI: 10.1007/s10585-021-10100-3] [Reference Citation Analysis]
9 Buonfiglioli A, Hambardzumyan D. Macrophages and microglia: the cerberus of glioblastoma. Acta Neuropathol Commun 2021;9:54. [PMID: 33766119 DOI: 10.1186/s40478-021-01156-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hyams DM, Cook RW, Buzaid AC. Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. J Surg Oncol 2019;119:175-86. [PMID: 30548543 DOI: 10.1002/jso.25319] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
11 Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M. Novel Immunotherapies for T Cell Lymphoma and Leukemia. Curr Hematol Malig Rep 2018;13:494-506. [PMID: 30317410 DOI: 10.1007/s11899-018-0480-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
12 Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol 2019;5:1008-19. [PMID: 31021376 DOI: 10.1001/jamaoncol.2019.0393] [Cited by in Crossref: 198] [Cited by in F6Publishing: 155] [Article Influence: 198.0] [Reference Citation Analysis]
13 Lorenzi M, Arndorfer S, Aguiar-Ibañez R, Scherrer E, Liu FX, Krepler C. An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma. J Drug Assess 2019;8:135-45. [PMID: 31489255 DOI: 10.1080/21556660.2019.1649266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Shen S, Hadley M, Ustinova K, Pavlicek J, Knox T, Noonepalle S, Tavares MT, Zimprich CA, Zhang G, Robers MB, Bařinka C, Kozikowski AP, Villagra A. Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. J Med Chem 2019;62:8557-77. [PMID: 31414801 DOI: 10.1021/acs.jmedchem.9b00946] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
15 Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD, Wong W, Saenger YM. Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. Am J Clin Dermatol 2020;21:1-11. [PMID: 31602560 DOI: 10.1007/s40257-019-00475-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Krishnamoorthy M, Lenehan JG, Maleki Vareki S. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges. J Natl Cancer Inst 2021;113:823-32. [PMID: 33432320 DOI: 10.1093/jnci/djaa216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
17 Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23:510-519. [PMID: 31863227 DOI: 10.1007/s10120-019-01034-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
18 Hu J, Yu H, Sun L, Yan Y, Zhang L, Jiang G, Zhang P. Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma. Front Oncol 2021;11:650853. [PMID: 33996569 DOI: 10.3389/fonc.2021.650853] [Reference Citation Analysis]
19 Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Front Oncol 2019;9:396. [PMID: 31139574 DOI: 10.3389/fonc.2019.00396] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 24.0] [Reference Citation Analysis]
20 Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM, Tobin RP, Nassar K, Shellman YG, Kim J, Medina TM, Rioth M, Lewis KD, McCarter MD, Gonzalez R, Tan AC, Robinson WA. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers (Basel) 2020;12:E1943. [PMID: 32708981 DOI: 10.3390/cancers12071943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Patrinely JR Jr, Dewan AK, Johnson DB. The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs 2020;34:495-503. [PMID: 32447657 DOI: 10.1007/s40259-020-00428-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7:2. [PMID: 30612580 DOI: 10.1186/s40425-018-0478-8] [Cited by in Crossref: 99] [Cited by in F6Publishing: 74] [Article Influence: 49.5] [Reference Citation Analysis]
23 Flynn M, Pickering L, Larkin J, Turajlic S. Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Ther Adv Med Oncol 2018;10:1758835918777427. [PMID: 29977349 DOI: 10.1177/1758835918777427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Paulson KG, Lahman MC, Chapuis AG, Brownell I. Immunotherapy for skin cancer. Int Immunol 2019;31:465-75. [PMID: 30753483 DOI: 10.1093/intimm/dxz012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 24.0] [Reference Citation Analysis]
25 Tran TB, Maker VK, Maker AV. Impact of Immunotherapy after Resection of Pancreatic Cancer. J Am Coll Surg 2019;229:19-27.e1. [PMID: 30742911 DOI: 10.1016/j.jamcollsurg.2019.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Uhara H. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. Int J Clin Oncol 2019;24:1508-14. [PMID: 29470725 DOI: 10.1007/s10147-018-1246-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Verver D, van der Veldt A, van Akkooi A, Verhoef C, Grünhagen DJ, Louwman WJ. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study. Int J Cancer 2020;146:26-34. [PMID: 30801710 DOI: 10.1002/ijc.32229] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
28 Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung ST, Nathan P, Matin RN, Chuchu N, Chan SA, Durack A, Bayliss SE, Gulati A, Patel L, Davenport C, Godfrey K, Subesinghe M, Traill Z, Deeks JJ, Williams HC; Cochrane Skin Cancer Diagnostic Test Accuracy Group. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database Syst Rev 2019;7:CD012806. [PMID: 31260100 DOI: 10.1002/14651858.CD012806.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Smylie MG. Use of immuno-oncology in melanoma. Curr Oncol 2020;27:S51-8. [PMID: 32368174 DOI: 10.3747/co.27.5135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist 2020;25:e398-404. [PMID: 32162817 DOI: 10.1634/theoncologist.2018-0883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
31 Giles KM, Rosenbaum BE, Berger M, Izsak A, Li Y, Illa Bochaca I, Vega-Saenz de Miera E, Wang J, Darvishian F, Zhong H, Osman I. Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma. J Invest Dermatol 2019;139:430-8. [PMID: 30148988 DOI: 10.1016/j.jid.2018.07.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
32 Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 2020;19:533-52. [PMID: 32528145 DOI: 10.1038/s41573-020-0068-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 84] [Article Influence: 108.0] [Reference Citation Analysis]
33 Bregman B, Teitsson S, Orsini I, Cotté FE, Amadi A, Moshyk A, Roze S, Gaudin AF. Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France. Dermatol Ther (Heidelb) 2020;10:1331-43. [PMID: 32920709 DOI: 10.1007/s13555-020-00446-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Navani V, Graves MC, Bowden NA, Van Der Westhuizen A. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. Br J Clin Pharmacol 2020;86:1736-52. [PMID: 32384184 DOI: 10.1111/bcp.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019;17:661-674. [PMID: 31205619 DOI: 10.1016/j.csbj.2019.03.006] [Cited by in Crossref: 98] [Cited by in F6Publishing: 88] [Article Influence: 49.0] [Reference Citation Analysis]
36 Klein O, Brown WA, Saxon S, Haydon A. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. Oncologist 2021;26:461-4. [PMID: 33856094 DOI: 10.1002/onco.13793] [Reference Citation Analysis]
37 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Tonella L, Pala V, Ponti R, Rubatto M, Gallo G, Mastorino L, Avallone G, Merli M, Agostini A, Fava P, Bertero L, Senetta R, Osella-Abate S, Ribero S, Fierro MT, Quaglino P. Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. Int J Mol Sci 2021;22:4561. [PMID: 33925387 DOI: 10.3390/ijms22094561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Ascierto PA, Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I. The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. J Transl Med 2018;16:101. [PMID: 29665799 DOI: 10.1186/s12967-018-1477-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
40 Asher N, Ben-Betzalel G, Lev-Ari S, Shapira-Frommer R, Steinberg-Silman Y, Gochman N, Schachter J, Meirson T, Markel G. Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. Cancers (Basel) 2020;12:E2329. [PMID: 32824780 DOI: 10.3390/cancers12082329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
41 Saldanha G, Yarrow J, Pancholi J, Flatman K, Teo KW, Elsheik S, Harrison R, O'Riordan M, Bamford M. Breslow Density Is a Novel Prognostic Feature That Adds Value to Melanoma Staging. Am J Surg Pathol 2018;42:715-25. [PMID: 29462090 DOI: 10.1097/PAS.0000000000001034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
42 Dummer R, Mangana J, Frauchiger AL, Lang C, Micaletto S, Barysch MJ. How I treat metastatic melanoma. ESMO Open 2019;4:e000509. [PMID: 31423341 DOI: 10.1136/esmoopen-2019-000509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Tikkanen A, Iivanainen S, Koivunen JP. Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers. J Cancer Res Clin Oncol 2020;146:2153-60. [PMID: 32306129 DOI: 10.1007/s00432-020-03217-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Kwak M, Farrow NE, Salama AKS, Mosca PJ, Hanks BA, Slingluff CL, Beasley GM. Updates in adjuvant systemic therapy for melanoma. J Surg Oncol 2019;119:222-31. [PMID: 30481375 DOI: 10.1002/jso.25298] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
45 Vivarelli S, Falzone L, Leonardi GC, Salmeri M, Libra M. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). Int J Oncol 2021;59:75. [PMID: 34396439 DOI: 10.3892/ijo.2021.5255] [Reference Citation Analysis]
46 Stellato D, Thabane M, Eichten C, Delea TE. Preferences of Canadian patients and physicians for adjuvant treatments for melanoma. Curr Oncol 2019;26:e755-65. [PMID: 31896946 DOI: 10.3747/co.26.5085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Broman KK, Bettampadi D, Pérez-Morales J, Sun J, Kirichenko D, Carr MJ, Eroglu Z, Tarhini AA, Khushalani N, Schabath MB, Sarnaik A, Sondak VK, Zager JS. Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. Ann Surg Oncol 2021. [PMID: 34363118 DOI: 10.1245/s10434-021-10570-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Dillman RO, Cornforth AN, McClay EF, Depriest C. Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Manag 2019;6:MMT20. [PMID: 31406564 DOI: 10.2217/mmt-2018-0010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Des Devel Ther 2020;14:3625-49. [PMID: 32982171 DOI: 10.2147/DDDT.S267433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
50 Lu J, Li L, Lan Y, Liang Y, Meng H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med. 2019;8:7503-7515. [PMID: 31679184 DOI: 10.1002/cam4.2661] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
51 Kim J, Kim B, Kang SY, Heo YJ, Park SH, Kim ST, Kang WK, Lee J, Kim KM. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. Front Oncol. 2020;10:314. [PMID: 32232003 DOI: 10.3389/fonc.2020.00314] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
52 Rossi E, Schinzari G, Maiorano BA, Indellicati G, Di Stefani A, Pagliara MM, Fragomeni SM, De Luca EV, Sammarco MG, Garganese G, Galli J, Blasi MA, Paludetti G, Scambia G, Peris K, Tortora G. Efficacy of immune checkpoint inhibitors in different types of melanoma. Hum Vaccin Immunother 2021;17:4-13. [PMID: 32663057 DOI: 10.1080/21645515.2020.1771986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
53 Tokumitsu R, Hirakawa T, Yano M, Kirakosyan E, Sato S, Nasu K, Narahara H. A Case of Vaginal Malignant Melanoma Completely Resected by Radical Surgery. Am J Case Rep 2020;21:e927462. [PMID: 33085655 DOI: 10.12659/AJCR.927462] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Hoffmann F, Zarbl R, Niebel D, Sirokay J, Fröhlich A, Posch C, Holderried TAW, Brossart P, Saavedra G, Kuster P, Strieth S, Gielen GH, Ring SS, Dietrich J, Pietsch T, Flatz L, Kristiansen G, Landsberg J, Dietrich D. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clin Epigenetics 2020;12:94. [PMID: 32586358 DOI: 10.1186/s13148-020-00883-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
55 Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Müller-Brenne T, Schadendorf D, Utikal J, Wagner T, Augustin M. The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. Oncotarget 2018;9:26217-25. [PMID: 29899854 DOI: 10.18632/oncotarget.25439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
56 Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol 2021;39:2656-66. [PMID: 33979178 DOI: 10.1200/JCO.21.00612] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Najjar YG, Puligandla M, Lee SJ, Kirkwood JM. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer 2019;125:3013-24. [PMID: 31067358 DOI: 10.1002/cncr.32162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
58 Eriksson H, Utjés D, Olofsson Bagge R, Gillgren P, Isaksson K, Lapins J, Schultz IL, Lyth J, Andersson TM. The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden. Cancers (Basel) 2021;13:2456. [PMID: 34070092 DOI: 10.3390/cancers13102456] [Reference Citation Analysis]
59 Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, Ferrajolo C, Rafaniello C, Sportiello L, Rossi F, Capuano A. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol 2020;11:830. [PMID: 32581796 DOI: 10.3389/fphar.2020.00830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Eroglu Z, Ozgun A. Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. Expert Opin Orphan Drugs 2018;6:545-51. [PMID: 30574432 DOI: 10.1080/21678707.2018.1512402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
61 Yokota K, Uchi H, Uhara H, Yoshikawa S, Takenouchi T, Inozume T, Ozawa K, Ihn H, Fujisawa Y, Qureshi A, de Pril V, Otsuka Y, Weber J, Yamazaki N. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study. J Dermatol 2019;46:1197-201. [PMID: 31638282 DOI: 10.1111/1346-8138.15103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
62 Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, Peris K, Puig S, Menin C, De Nicolo A, Rodolfo M, Pellegrini C, Pastorino L, Evangelou E, Zhang T, Hua X, DellaValle CT, Timothy Bishop D, MacGregor S, Iles MI, Law MH, Cust A, Brown KM, Stratigos AJ, Nagore E, Chanock S, Shi J, Consortium MM, Consortium M, Landi MT. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Hum Mol Genet 2018;27:4145-56. [PMID: 30060076 DOI: 10.1093/hmg/ddy282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
63 Chick RC, Faries MB, Hale DF, Kemp Bohan PM, Hickerson AT, Vreeland TJ, Myers JW 3rd, Cindass JL, Brown TA 2nd, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Clifton GT, Park H, Sloan AJ, Wagner T, Peoples GE. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis. Cancer Med 2021;10:4302-11. [PMID: 33982452 DOI: 10.1002/cam4.3969] [Reference Citation Analysis]
64 Terheyden P, Krackhardt A, Eigentler T. The Systemic Treatment of Melanoma. Dtsch Arztebl Int 2019;116:497-504. [PMID: 31452501 DOI: 10.3238/arztebl.2019.0497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
65 Moore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, Saenger YM. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Sci Rep 2021;11:2809. [PMID: 33531581 DOI: 10.1038/s41598-021-82305-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Zhang H, Wang Y, Zheng Q, Tang K, Fang R, Wang Y, Sun Q. Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis. Front Oncol 2021;11:629687. [PMID: 33680968 DOI: 10.3389/fonc.2021.629687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Sahni S, Valecha G, Sahni A. Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. Cureus 2018;10:e3700. [PMID: 30788189 DOI: 10.7759/cureus.3700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
68 Garutti M, Buriolla S, Bertoli E, Vitale MG, Rossi E, Schinzari G, Minisini AM, Puglisi F. "To Anticipate": Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. Cancers (Basel) 2020;12:E1941. [PMID: 32708968 DOI: 10.3390/cancers12071941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
69 Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 2018;18:775-84. [PMID: 29923435 DOI: 10.1080/14737140.2018.1489246] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 21.0] [Reference Citation Analysis]
70 Kardos GR, Gowda R, Dinavahi SS, Kimball S, Robertson GP. Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery. Front Oncol 2020;10:834. [PMID: 32637352 DOI: 10.3389/fonc.2020.00834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
71 Ascierto PA, Butterfield LH, Campbell K, Daniele B, Dougan M, Emens LA, Formenti S, Janku F, Khleif SN, Kirchhoff T, Morabito A, Najjar Y, Nathan P, Odunsi K, Patnaik A, Paulos CM, Reinfeld BI, Skinner HD, Timmerman J, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). J Transl Med 2021;19:13. [PMID: 33407605 DOI: 10.1186/s12967-020-02627-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Bartlett EK. Current management of regional lymph nodes in patients with melanoma. J Surg Oncol 2019;119:200-7. [PMID: 30481384 DOI: 10.1002/jso.25316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
73 Zhou JG, Liang B, Liu JG, Jin SH, He SS, Frey B, Gu N, Fietkau R, Hecht M, Ma H, Gaipl US. Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy. Cells 2021;10:977. [PMID: 33922038 DOI: 10.3390/cells10050977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 DeLong RK, Cheng YH, Pearson P, Lin Z, Coffee C, Mathew EN, Hoffman A, Wouda RM, Higginbotham ML. Translating Nanomedicine to Comparative Oncology-the Case for Combining Zinc Oxide Nanomaterials with Nucleic Acid Therapeutic and Protein Delivery for Treating Metastatic Cancer. J Pharmacol Exp Ther 2019;370:671-81. [PMID: 31040175 DOI: 10.1124/jpet.118.256230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, Lo S, Carlino M, Palendira U, Scolyer RA, Long GV, Menzies AM. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. J Immunother Cancer 2020;8:e001488. [PMID: 33234603 DOI: 10.1136/jitc-2020-001488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
76 Trager MH, Coley SM, Dube G, Khan S, Ingham M, Samie FH, Geskin LJ, McDonnell D, Brouder D, Saenger Y, Carvajal R. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. J Immunother Cancer 2020;8:e000908. [PMID: 32503950 DOI: 10.1136/jitc-2020-000908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
77 Takayasu Y, Kubo N, Shino M, Nikkuni O, Ida S, Musha A, Takahashi K, Hirato J, Shirai K, Saitoh JI, Yokoo S, Chikamatsu K, Ohno T, Nakano T; Working Group on Head and Neck Tumors. Carbon-ion radiotherapy combined with chemotherapy for head and neck mucosal melanoma: Prospective observational study. Cancer Med 2019;8:7227-35. [PMID: 31621203 DOI: 10.1002/cam4.2614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
78 Autio KA, Boni V, Humphrey RW, Naing A. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clin Cancer Res 2020;26:984-9. [PMID: 31601568 DOI: 10.1158/1078-0432.CCR-19-1457] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 17.5] [Reference Citation Analysis]
79 Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4:1721-1728. [PMID: 30242316 DOI: 10.1001/jamaoncol.2018.3923] [Cited by in Crossref: 614] [Cited by in F6Publishing: 515] [Article Influence: 307.0] [Reference Citation Analysis]
80 Echegaray JJ, Yeaney G, Chen R, Singh AD. Conjunctival Melanoma Angiotropic Microsatellitosis: A Mechanism of Local Extravascular Migratory Metastasis. Ocul Oncol Pathol 2020;6:287-92. [PMID: 33005619 DOI: 10.1159/000505270] [Reference Citation Analysis]
81 Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 2019;145:511-21. [PMID: 30539281 DOI: 10.1007/s00432-018-2819-x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 73] [Article Influence: 31.3] [Reference Citation Analysis]
82 Ando Y, Hayashi T, Sugimoto R, Nishibe S, Ito K, Kawada K, Ikeda Y, Yamada S, Imaizumi K. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest New Drugs 2020;38:1200-6. [PMID: 31823160 DOI: 10.1007/s10637-019-00881-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
83 Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6:143. [PMID: 29862232 DOI: 10.21037/atm.2018.02.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
84 Patrinely JR Jr, McGuigan B, Chandra S, Fenton SE, Chowdhary A, Kennedy LB, Mooradian MJ, Palmeri M, Portal D, Horst SN, Scoville EA, Long GV, Shi C, Mehnert JM, Sullivan RJ, Salama AK, Sosman JA, Menzies AM, Johnson DB. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 2021;10:1875639. [PMID: 33628621 DOI: 10.1080/2162402X.2021.1875639] [Reference Citation Analysis]
85 Marra A, Scognamiglio G, Peluso I, Botti G, Fusciello C, Filippelli A, Ascierto PA, Pepe S, Sabbatino F. Immune Checkpoint Inhibitors in Melanoma and HIV Infection. Open AIDS J 2017;11:91-100. [PMID: 29290886 DOI: 10.2174/1874613601711010091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
86 Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med 2018;16:207. [PMID: 30031393 DOI: 10.1186/s12967-018-1568-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
87 Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Schilling B, Loquai C, Berking C, Hüning S, Schatton K, Gebhardt C, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, Nikfarjam U, Erdmann M, Stang A, Kowall B, Roesch A, Ugurel S, Zimmer L, Schadendorf D, Livingstone E. Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. Cancers (Basel) 2021;13:2319. [PMID: 34065995 DOI: 10.3390/cancers13102319] [Reference Citation Analysis]
88 Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunol Res 2020;8:70-80. [PMID: 31699709 DOI: 10.1158/2326-6066.CIR-19-0545] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
89 Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang YQ, Xie C. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:650292. [PMID: 33968750 DOI: 10.3389/fonc.2021.650292] [Reference Citation Analysis]
90 Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 2020;8:e001322. [PMID: 33144335 DOI: 10.1136/jitc-2020-001322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
91 Mandalà M, Rutkowski P. Rational combination of cancer immunotherapy in melanoma. Virchows Arch 2019;474:433-47. [PMID: 30552520 DOI: 10.1007/s00428-018-2506-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
92 Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, Thakur R, Wargo JA, Cloughesy TF, Prins RM, Heath JR. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun 2021;12:4031. [PMID: 34188042 DOI: 10.1038/s41467-021-24293-4] [Reference Citation Analysis]
93 Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? J Immunother Cancer 2020;8:e000475. [PMID: 32238471 DOI: 10.1136/jitc-2019-000475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
94 Cheng TW, Yu NY, Seetharam M, Patel SH. Radiotherapy for malignant melanoma of the lacrimal sac. Rare Tumors 2020;12:2036361320971943. [PMID: 33240474 DOI: 10.1177/2036361320971943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
95 Zhao B, Zhao H, Zhao J. Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. Ther Adv Med Oncol 2020;12:1758835919895753. [PMID: 32082425 DOI: 10.1177/1758835919895753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
96 De Logu F, Galli F, Nassini R, Ugolini F, Simi S, Cossa M, Miracco C, Gianatti A, De Giorgi V, Rulli E, Cossu A, Massi D, Mandalà M. Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients. Cells 2021;10:422. [PMID: 33671367 DOI: 10.3390/cells10020422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Tang SQ, Tang LL, Mao YP, Li WF, Chen L, Zhang Y, Guo Y, Liu Q, Sun Y, Xu C, Ma J. The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. Cancer Res Treat 2021;53:339-54. [PMID: 33171025 DOI: 10.4143/crt.2020.790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
98 Toor K, Middleton MR, Chan K, Amadi A, Moshyk A, Kotapati S. Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis. BMC Cancer 2021;21:3. [PMID: 33402121 DOI: 10.1186/s12885-020-07538-1] [Reference Citation Analysis]
99 Featherston C, Nardi WS, Tomé FR, Quildrian SD. Role of sentinel lymph node biopsy for cutaneous melanoma in elderly patients: preliminary results in a Latin-American population. Ecancermedicalscience 2021;15:1167. [PMID: 33680081 DOI: 10.3332/ecancer.2021.1167] [Reference Citation Analysis]
100 Huang Q, Zheng Y, Gao Z, Yuan L, Sun Y, Chen H. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. J Cancer 2021;12:1133-43. [PMID: 33442411 DOI: 10.7150/jca.49325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Hawkins ML, Rioth MJ, Eguchi MM, Cockburn M. Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment. J Am Acad Dermatol 2019;80:1640-9. [PMID: 30654077 DOI: 10.1016/j.jaad.2019.01.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
102 Ottaviano M, De Placido S, Ascierto PA. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Arch 2019;474:421-32. [PMID: 30747264 DOI: 10.1007/s00428-019-02538-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
103 Du X, Liu M, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, Zheng P. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Res 2018;28:433-47. [PMID: 29463898 DOI: 10.1038/s41422-018-0012-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
104 Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. J Immunother Cancer 2018;6:38. [PMID: 29773080 DOI: 10.1186/s40425-018-0345-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
105 Chacon AC, Melucci AD, Qin SS, Prieto PA. Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. Int J Mol Sci 2021;22:3228. [PMID: 33810078 DOI: 10.3390/ijms22063228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Kulkarni PM, Robinson EJ, Sarin Pradhan J, Gartrell-Corrado RD, Rohr BR, Trager MH, Geskin LJ, Kluger HM, Wong PF, Acs B, Rizk EM, Yang C, Mondal M, Moore MR, Osman I, Phelps R, Horst BA, Chen ZS, Ferringer T, Rimm DL, Wang J, Saenger YM. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. Clin Cancer Res 2020;26:1126-34. [PMID: 31636101 DOI: 10.1158/1078-0432.CCR-19-1495] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
107 Huang Y, Fan H, Li N, Du J. Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis. Cancer Med 2019;8:2664-74. [PMID: 30950194 DOI: 10.1002/cam4.2104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
108 Keller J, Schwartz TL, Lizalek JM, Chang ES, Patel AD, Hurley MY, Hsueh EC. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med 2019;8:2205-12. [PMID: 30950242 DOI: 10.1002/cam4.2128] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
109 Nakamura Y. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Front Med (Lausanne) 2019;6:119. [PMID: 31192215 DOI: 10.3389/fmed.2019.00119] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 29.5] [Reference Citation Analysis]
110 Raimondo S, Pucci M, Alessandro R, Fontana S. Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. Int J Mol Sci 2020;21:E2286. [PMID: 32225076 DOI: 10.3390/ijms21072286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
111 Nelson DW, Faries MB. ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma? Ann Surg Oncol 2019;26:4619-20. [PMID: 31531796 DOI: 10.1245/s10434-019-07711-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Jia DD, Niu Y, Zhu H, Wang S, Ma T, Li T. Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. Front Oncol 2021;11:675873. [PMID: 34221994 DOI: 10.3389/fonc.2021.675873] [Reference Citation Analysis]
113 Mineiro Dos Santos Garrett NF, Carvalho da Costa AC, Barros Ferreira E, Damiani G, Diniz Dos Reis PE, Inocêncio Vasques C. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLoS One 2021;16:e0255716. [PMID: 34358260 DOI: 10.1371/journal.pone.0255716] [Reference Citation Analysis]
114 Komiya T, Huang CH. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. Front Oncol 2018;8:423. [PMID: 30338242 DOI: 10.3389/fonc.2018.00423] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 29.0] [Reference Citation Analysis]
115 Suresh K, Naidoo J, Lin CT, Danoff S. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest 2018;154:1416-23. [PMID: 30189190 DOI: 10.1016/j.chest.2018.08.1048] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 24.3] [Reference Citation Analysis]
116 Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Melanoma models for the next generation of therapies. Cancer Cell 2021;39:610-31. [PMID: 33545064 DOI: 10.1016/j.ccell.2021.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
117 Keung EZ, Gershenwald JE. Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. J Natl Cancer Inst 2020;112:875-85. [PMID: 32061122 DOI: 10.1093/jnci/djaa012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
118 Bloemendal M, Rietveld MJA, van Willigen WW, Gerritsen WR, Figdor CG, Bonenkamp JJ, Westdorp H, Boudewijns S, Koornstra RHT, Adang EMM, Schreibelt G, Ottevanger PB, de Vries IJM, Bol KF. Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. Clin Transl Oncol 2019;21:774-80. [PMID: 30465182 DOI: 10.1007/s12094-018-1987-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Nsengimana J, Laye J, Filia A, O'Shea S, Muralidhar S, Poźniak J, Droop A, Chan M, Walker C, Parkinson L, Gascoyne J, Mell T, Polso M, Jewell R, Randerson-Moor J, Cook GP, Bishop DT, Newton-Bishop J. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J Clin Invest 2018;128:2048-63. [PMID: 29664013 DOI: 10.1172/JCI95351] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 14.3] [Reference Citation Analysis]
120 Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol 2021;3:35-47. [PMID: 33842895 DOI: 10.1016/j.jaccao.2020.11.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
121 Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2020;6:519-27. [PMID: 31895407 DOI: 10.1001/jamaoncol.2019.5570] [Cited by in Crossref: 100] [Cited by in F6Publishing: 74] [Article Influence: 100.0] [Reference Citation Analysis]
122 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
123 Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24:1649-54. [PMID: 30297909 DOI: 10.1038/s41591-018-0197-1] [Cited by in Crossref: 301] [Cited by in F6Publishing: 238] [Article Influence: 100.3] [Reference Citation Analysis]
124 Naik PP. Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. Dermatol Ther (Heidelb) 2021. [PMID: 34339016 DOI: 10.1007/s13555-021-00583-z] [Reference Citation Analysis]
125 Kim H, Lee S, Cha IH, Kim HJ, Nam W. Primary malignant mucosal melanoma of the maxillofacial area. J Korean Assoc Oral Maxillofac Surg 2021;47:76-81. [PMID: 33911039 DOI: 10.5125/jkaoms.2021.47.2.76] [Reference Citation Analysis]
126 Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021;80:36-48. [PMID: 32327425 DOI: 10.1136/annrheumdis-2020-217139] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 32.0] [Reference Citation Analysis]
127 Perez-Gracia JL, Sanmamed MF, Melero I. Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better? Transl Lung Cancer Res 2018;7:S356-7. [PMID: 30705854 DOI: 10.21037/tlcr.2018.10.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
128 Testori AAE, Chiellino S, van Akkooi ACJ. Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. Cancers (Basel) 2020;12:E1994. [PMID: 32708268 DOI: 10.3390/cancers12071994] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
129 Kwon M, Choi YJ, Sa M, Park SH, Shin EC. Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. Immune Netw 2018;18:e45. [PMID: 30619631 DOI: 10.4110/in.2018.18.e45] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
130 Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, Kristiansen G, Landsberg J, Dietrich D. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. JCI Insight 2018;3:96793. [PMID: 29997292 DOI: 10.1172/jci.insight.96793] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
131 Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clin Cancer Res 2019;25:2442-9. [PMID: 30617133 DOI: 10.1158/1078-0432.CCR-18-2652] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 19.5] [Reference Citation Analysis]
132 Fujikawa I, Ando T, Suzuki-Karasaki M, Suzuki-Karasaki M, Ochiai T, Suzuki-Karasaki Y. Aspirin Induces Mitochondrial Ca2+ Remodeling in Tumor Cells via ROS‒Depolarization‒Voltage-Gated Ca2+ Entry. Int J Mol Sci 2020;21:E4771. [PMID: 32635638 DOI: 10.3390/ijms21134771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, Wojcik K, Chapuis AG, Thompson JA, Madeleine MM, Gardner JM. Age-Specific Incidence of Melanoma in the United States. JAMA Dermatol 2020;156:57-64. [PMID: 31721989 DOI: 10.1001/jamadermatol.2019.3353] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 36.0] [Reference Citation Analysis]
134 Rapport F, Smith AL, Cust AE, Mann GJ, Watts CG, Gyorki DE, Henderson M, Hong AM, Kelly JW, Long GV, Mar VJ, Morton RL, Saw RP, Scolyer RA, Spillane AJ, Thompson JF, Braithwaite J. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open 2020;10:e032636. [PMID: 32111612 DOI: 10.1136/bmjopen-2019-032636] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Kim K, Khang D. Past, Present, and Future of Anticancer Nanomedicine. Int J Nanomedicine 2020;15:5719-43. [PMID: 32821098 DOI: 10.2147/IJN.S254774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
136 Mulder EEAP, Dwarkasing JT, Tempel D, van der Spek A, Bosman L, Verver D, Mooyaart AL, van der Veldt AAM, Verhoef C, Nijsten TEC, Grunhagen DJ, Hollestein LM. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. Br J Dermatol 2021;184:944-51. [PMID: 32844403 DOI: 10.1111/bjd.19499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
137 Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data. Adv Ther 2019;36:2783-96. [PMID: 31440980 DOI: 10.1007/s12325-019-01060-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
138 Sun L, Chin RI, Gastman B, Thorstad W, Yom SS, Reddy CA, Nussenbaum B, Wang SJ, Knackstedt T, Vidimos AT, Koyfman SA, Manyam BV. Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. JAMA Dermatol 2019;155:442-7. [PMID: 30810715 DOI: 10.1001/jamadermatol.2018.5453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
139 Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol 2019;30:804-14. [PMID: 30838379 DOI: 10.1093/annonc/mdz048] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 40.0] [Reference Citation Analysis]
140 Lo SN, Ma J, Scolyer RA, Haydu LE, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Ch'ng S, Mann GJ, Gershenwald JE, Thompson JF, Varey AHR. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol 2020;38:2719-27. [PMID: 32530761 DOI: 10.1200/JCO.19.02362] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 19.0] [Reference Citation Analysis]
141 Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472-92. [PMID: 29028110 DOI: 10.3322/caac.21409] [Cited by in Crossref: 865] [Cited by in F6Publishing: 622] [Article Influence: 216.3] [Reference Citation Analysis]
142 Gorris S, Perdaens C, Delvaux V, Poorten VV, Neyns B, Baron I. A Solitary Melanoma Metastasis Confined to the Submandibular Gland. Case Rep Oncol 2021;14:957-62. [PMID: 34267640 DOI: 10.1159/000516796] [Reference Citation Analysis]
143 Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.Rheumatology (Oxford). 2019;58:vii59-vii67. [PMID: 31816080 DOI: 10.1093/rheumatology/kez308] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 43.0] [Reference Citation Analysis]
144 Aiken TJ, Stahl CC, Schwartz PB, Barrett J, Acher AW, Lemaster D, Leverson G, Weber S, Neuman H, Abbott DE. Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma. J Surg Oncol 2021;123:104-9. [PMID: 32939750 DOI: 10.1002/jso.26225] [Reference Citation Analysis]
145 Zucali PA, Cordua N, D'Antonio F, Borea F, Perrino M, De Vincenzo F, Santoro A. Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. Front Oncol 2020;10:568279. [PMID: 33194654 DOI: 10.3389/fonc.2020.568279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Khunger A, Buchwald ZS, Lowe M, Khan MK, Delman KA, Tarhini AA. Neoadjuvant therapy of locally/regionally advanced melanoma. Ther Adv Med Oncol 2019;11:1758835919866959. [PMID: 31391869 DOI: 10.1177/1758835919866959] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
147 Fountain E, Bassett RL, Cain S, Posada L, Gombos DS, Hwu P, Bedikian A, Patel SP. Adjuvant Ipilimumab in High-Risk Uveal Melanoma. Cancers (Basel) 2019;11:E152. [PMID: 30699934 DOI: 10.3390/cancers11020152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
148 Wieland A, Kamphorst AO, Adsay NV, Masor JJ, Sarmiento J, Nasti TH, Darko S, Douek DC, Xue Y, Curran WJ, Lawson DH, Ahmed R. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient. Cancer Immunol Immunother 2018;67:1767-76. [PMID: 30167863 DOI: 10.1007/s00262-018-2228-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
149 Suo A, Chan Y, Beaulieu C, Kong S, Cheung WY, Monzon JG, Smylie M, Walker J, Morris D, Cheng T. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma. Oncologist 2020;25:438-46. [PMID: 32048768 DOI: 10.1634/theoncologist.2019-0674] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
150 Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). J Transl Med 2019;17:234. [PMID: 31331337 DOI: 10.1186/s12967-019-1979-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
151 Maio M, Lahn M, Di Giacomo AM, Covre A, Calabrò L, Ibrahim R, Fox B; Siena Think Tank. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. J Exp Clin Cancer Res 2021;40:240. [PMID: 34301276 DOI: 10.1186/s13046-021-02023-4] [Reference Citation Analysis]
152 Ellis R, Tang D, Nasr B, Greenwood A, McConnell A, Anagnostou ME, Elias M, Verykiou S, Bajwa D, Ewen T, Reynolds NJ, Barrett P, Carling E, Watson G, Armstrong J, Allen AJ, Horswell S, Labus M, Lovat PE. Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas. Br J Dermatol 2020;182:156-65. [PMID: 31056744 DOI: 10.1111/bjd.18086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
153 Mitra S, Lauss M, Cabrita R, Choi J, Zhang T, Isaksson K, Olsson H, Ingvar C, Carneiro A, Staaf J, Ringnér M, Nielsen K, Brown KM, Jönsson G. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. Mol Oncol 2020;14:933-50. [PMID: 32147909 DOI: 10.1002/1878-0261.12663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
154 Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C. New paradigm for stage III melanoma: from surgery to adjuvant treatment. J Transl Med 2019;17:266. [PMID: 31412885 DOI: 10.1186/s12967-019-2012-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
155 Mediratta K, El-Sahli S, D'Costa V, Wang L. Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E3529. [PMID: 33256070 DOI: 10.3390/cancers12123529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
156 Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, Panageas KS. Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. Ann Surg Oncol 2018;25:2172-7. [PMID: 29470818 DOI: 10.1245/s10434-018-6370-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
157 Nebhan CA, Johnson DB. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. Expert Rev Anticancer Ther 2020;20:137-45. [PMID: 31997676 DOI: 10.1080/14737140.2020.1724539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
158 Iivanainen S, Koivunen JP. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. Int J Mol Sci 2020;21:E556. [PMID: 31952311 DOI: 10.3390/ijms21020556] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
159 Strome AL, Zhang X, Strome SE. The evolving role of immuno-oncology for the treatment of head and neck cancer. Laryngoscope Investig Otolaryngol 2019;4:62-9. [PMID: 30828620 DOI: 10.1002/lio2.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
160 Ali Z, Zafar MU, Wolfe Z, Akbar F, Lash B. Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature. Cureus 2020;12:e11246. [PMID: 33274128 DOI: 10.7759/cureus.11246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
161 Gowen MF, Giles KM, Simpson D, Tchack J, Zhou H, Moran U, Dawood Z, Pavlick AC, Hu S, Wilson MA, Zhong H, Krogsgaard M, Kirchhoff T, Osman I. Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. J Transl Med 2018;16:82. [PMID: 29606147 DOI: 10.1186/s12967-018-1452-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 13.7] [Reference Citation Analysis]
162 Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A 3rd, Mulcahy M. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist. 2020;25:e808-e815. [PMID: 31740568 DOI: 10.1634/theoncologist.2019-0473] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
163 Popp FC, Capino I, Bartels J, Damanakis A, Li J, Datta RR, Löser H, Zhao Y, Quaas A, Lohneis P, Bruns CJ, On Behalf Of The Pancalyze Study Group. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:2689. [PMID: 34072549 DOI: 10.3390/cancers13112689] [Reference Citation Analysis]
164 Giannini EG, Aglitti A, Borzio M, Gambato M, Guarino M, Iavarone M, Lai Q, Levi Sandri GB, Melandro F, Morisco F, Ponziani FR, Rendina M, Russo FP, Sacco R, Viganò M, Vitale A, Trevisani F; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers (Basel) 2019;11:E1689. [PMID: 31671581 DOI: 10.3390/cancers11111689] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
165 Zhao B, Zhao H, Zhao J. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events. J Immunother Cancer 2018;6:101. [PMID: 30285872 DOI: 10.1186/s40425-018-0421-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
166 Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett 2020;477:19-30. [PMID: 32120023 DOI: 10.1016/j.canlet.2020.02.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
167 Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol 2020;38:3925-36. [PMID: 32946353 DOI: 10.1200/JCO.20.02110] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 42.0] [Reference Citation Analysis]
168 Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murao N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 2019;8:2146-56. [PMID: 30932370 DOI: 10.1002/cam4.2110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
169 Lodde G, Zimmer L, Livingstone E, Schadendorf D, Ugurel S. [Malignant melanoma]. Pathologe 2020;41:281-92. [PMID: 32206873 DOI: 10.1007/s00292-020-00776-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J Clin Med. 2020;9:223. [PMID: 31947592 DOI: 10.3390/jcm9010223] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 32.0] [Reference Citation Analysis]
171 Lee AY, Brady MS. Neoadjuvant immunotherapy for melanoma. J Surg Oncol 2021;123:782-8. [PMID: 33002195 DOI: 10.1002/jso.26229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
172 Bajaj S, Donnelly D, Call M, Johannet P, Moran U, Polsky D, Shapiro R, Berman R, Pavlick A, Weber J, Zhong J, Osman I. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. J Natl Cancer Inst 2020;112:921-8. [PMID: 31977051 DOI: 10.1093/jnci/djaa008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
173 Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity 2018;48:434-52. [PMID: 29562194 DOI: 10.1016/j.immuni.2018.03.014] [Cited by in Crossref: 522] [Cited by in F6Publishing: 451] [Article Influence: 174.0] [Reference Citation Analysis]
174 Malissen N, Macagno N, Granjeaud S, Granier C, Moutardier V, Gaudy-Marqueste C, Habel N, Mandavit M, Guillot B, Pasero C, Tartour E, Ballotti R, Grob JJ, Olive D. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. Oncoimmunology 2019;8:e1665976. [PMID: 31741766 DOI: 10.1080/2162402X.2019.1665976] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
175 Boonstra PA, Wind TT, van Kruchten M, Schuuring E, Hospers GAP, van der Wekken AJ, de Groot DJ, Schröder CP, Fehrmann RSN, Reyners AKL. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer Metastasis Rev 2020;39:999-1013. [PMID: 32367253 DOI: 10.1007/s10555-020-09876-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
176 Chai QQ, Du JY, Zhu J, Wu B. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. Front Pharmacol 2019;10:1260. [PMID: 31708783 DOI: 10.3389/fphar.2019.01260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
177 Kurzhals JK, Graf T, Boch K, Grzyska U, Frydrychowicz A, Zillikens D, Terheyden P, Langan EA. Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. Front Med (Lausanne) 2021;8:691618. [PMID: 34291066 DOI: 10.3389/fmed.2021.691618] [Reference Citation Analysis]
178 Indini A, Rijavec E, Bareggi C, Grossi F. Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. J Thorac Dis 2020;12:3390-8. [PMID: 32642264 DOI: 10.21037/jtd.2020.02.46] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
179 van Willigen WW, Bloemendal M, Gerritsen WR, Schreibelt G, de Vries IJM, Bol KF. Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Front Immunol 2018;9:2265. [PMID: 30327656 DOI: 10.3389/fimmu.2018.02265] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 19.7] [Reference Citation Analysis]
180 Miller DM, Trowbridge RM, Desai A, Drews RE. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab. J Immunother Cancer 2018;6:122. [PMID: 30454071 DOI: 10.1186/s40425-018-0437-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
181 Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol 2021;28:3480-9. [PMID: 33856603 DOI: 10.1245/s10434-021-09804-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Latosinsky S, Allen B, Shariff SZ. Melanoma nodal management in Ontario the year after the 2012 American Society of Clinical Oncology and Society of Surgical Oncology guideline. Curr Oncol 2019;26:330-7. [PMID: 31708651 DOI: 10.3747/co.26.5123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
183 Sabbatino F, Scognamiglio G, Liguori L, Marra A, Anniciello AM, Polcaro G, Dal Col J, Caputo A, Peluso AL, Botti G, Zeppa P, Ferrone S, Pepe S. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. Front Immunol 2020;11:561390. [PMID: 33117345 DOI: 10.3389/fimmu.2020.561390] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Rabbie R, Ferguson P, Molina-Aguilar C, Adams DJ, Robles-Espinoza CD. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247:539-551. [PMID: 30511391 DOI: 10.1002/path.5213] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 29.5] [Reference Citation Analysis]
185 Leonardi GC, Candido S, Falzone L, Spandidos DA, Libra M. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol 2020;57:609-18. [PMID: 32582963 DOI: 10.3892/ijo.2020.5088] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 23.0] [Reference Citation Analysis]
186 Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S. Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. J Gastrointest Oncol 2018;9:1014-26. [PMID: 30603120 DOI: 10.21037/jgo.2018.05.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
187 Testa U, Castelli G, Pelosi E. Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Med Sci (Basel) 2017;5:E28. [PMID: 29156643 DOI: 10.3390/medsci5040028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
188 Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212528. [PMID: 29899754 DOI: 10.7573/dic.212528] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
189 Peric B, Milicevic S, Perhavec A, Hocevar M, Zgajnar J. Completely resected stage III melanoma controversy - 15 years of national tertiary centre experience. Radiol Oncol 2020;55:50-6. [PMID: 33885234 DOI: 10.2478/raon-2020-0056] [Reference Citation Analysis]
190 Ascierto PA, Agarwala SS, Eggermont A, Gershenwald JE, Grob JJ, Hamid O, Michielin O, Postow M, Puzanov I, Zarour HM, Caracò C, Testori A. The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. J Transl Med 2020;18:171. [PMID: 32299446 DOI: 10.1186/s12967-020-02340-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 2019;7:319. [PMID: 31753014 DOI: 10.1186/s40425-019-0774-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 26.0] [Reference Citation Analysis]
192 Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD, Urba WJ, Leidner RS. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 2019;7:165. [PMID: 31269983 DOI: 10.1186/s40425-019-0645-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 23.5] [Reference Citation Analysis]
193 Huang Y, Zhu L, Guo T, Chen W, Zhang Z, Li W, Pan X. Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. Hum Vaccin Immunother 2021;17:1278-87. [PMID: 33079622 DOI: 10.1080/21645515.2020.1823779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Liu Y, Zheng P. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. Trends Pharmacol Sci 2020;41:4-12. [PMID: 31836191 DOI: 10.1016/j.tips.2019.11.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
195 Yang L, Dong XZ, Xing XX, Cui XH, Li L, Zhang L. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis. World J Gastrointest Oncol 2020;12:1346-63. [PMID: 33250966 DOI: 10.4251/wjgo.v12.i11.1346] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
196 Kwa MQ, Herum KM, Brakebusch C. Cancer-associated fibroblasts: how do they contribute to metastasis? Clin Exp Metastasis 2019;36:71-86. [PMID: 30847799 DOI: 10.1007/s10585-019-09959-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
197 Eggermont AMM, Bellomo D, Arias-Mejias SM, Quattrocchi E, Sominidi-Damodaran S, Bridges AG, Lehman JS, Hieken TJ, Jakub JW, Murphree DH, Pittelkow MR, Sluzevich JC, Cappel MA, Bagaria SP, Perniciaro C, Tjien-Fooh FJ, Rentroia-Pacheco B, Wever R, van Vliet MH, Dwarkasing J, Meves A. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer 2020;140:11-8. [PMID: 33032086 DOI: 10.1016/j.ejca.2020.08.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
198 Endo F, Akiyama Y, Onishi M, Fujisawa R, Sasaki N, Nikai H, Baba S, Sugimoto R, Kimura T, Takahara T, Iwaya T, Otsuka K, Nitta H, Koeda K, Sugai T, Sasaki A. Primary esophageal malignant melanoma successfully treated with anti-PD-1 antibody for retroperitoneal recurrence after esophagectomy: A case report. Int J Surg Case Rep 2020;75:152-6. [PMID: 32950945 DOI: 10.1016/j.ijscr.2020.09.034] [Reference Citation Analysis]
199 Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. Cancer 2020;126:1166-74. [PMID: 31869447 DOI: 10.1002/cncr.32585] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
200 Martinez Pena GN, Jiang C. Endobronchial, laryngeal and mediastinal melanoma: a rare constellation of metastatic disease. BMJ Case Rep 2019;12:e228957. [PMID: 31068348 DOI: 10.1136/bcr-2018-228957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). BMJ Open 2018;8:e021701. [PMID: 30082356 DOI: 10.1136/bmjopen-2018-021701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
202 Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, Lambiase A, de Vincentiis M, Greco A. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res 2020;2020:9235638. [PMID: 32671117 DOI: 10.1155/2020/9235638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
203 Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol 2020;17:137-50. [PMID: 32020040 DOI: 10.1038/s41585-020-0282-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 40.0] [Reference Citation Analysis]
204 Hirshoren N, Yoeli R, Cohen JE, Weinberger JM, Kaplan N, Merims S, Peretz T, Lotem M. Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. PLoS One 2020;15:e0231038. [PMID: 32282861 DOI: 10.1371/journal.pone.0231038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Fonseca IB, Lindote MVN, Monteiro MR, Doria Filho E, Pinto CAL, Jafelicci AS, de Melo Lôbo M, Calsavara VF, Bertolli E, Duprat Neto JP. Sentinel Node Status is the Most Important Prognostic Information for Clinical Stage IIB and IIC Melanoma Patients. Ann Surg Oncol 2020;27:4133-40. [PMID: 32767223 DOI: 10.1245/s10434-020-08959-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Arai H, Nakajima TE. Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers (Basel) 2020;12:E1100. [PMID: 32354119 DOI: 10.3390/cancers12051100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
207 Lamichhane P, Deshmukh R, Brown JA, Jakubski S, Parajuli P, Nolan T, Raja D, Badawy M, Yoon T, Zmiyiwsky M, Lamichhane N. Novel Delivery Systems for Checkpoint Inhibitors. Medicines (Basel) 2019;6:E74. [PMID: 31373327 DOI: 10.3390/medicines6030074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
208 Sliker BH, Campbell PM. Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. Vaccines (Basel) 2021;9:634. [PMID: 34200702 DOI: 10.3390/vaccines9060634] [Reference Citation Analysis]
209 Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Clin Cancer Res 2019;25:1272-9. [PMID: 30630828 DOI: 10.1158/1078-0432.CCR-18-1680] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 12.5] [Reference Citation Analysis]
210 Tyrrell H, Payne M. Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Manag 2018;5:MMT11. [PMID: 30459941 DOI: 10.2217/mmt-2018-0003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
211 Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Holderried TAW, de Vos L, Bawden EG, Vogt TJ, Dietrich J, Zarbl R, Bootz F, Kristiansen G, Brossart P, Landsberg J, Dietrich D. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clin Epigenetics 2019;11:161. [PMID: 31747929 DOI: 10.1186/s13148-019-0752-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
213 Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, Cardalesi C, Rosanova M, De Placido P, Pietroluongo E, Riccio V, Mucci B, Parola S, Vitale MG, Palmieri G, Daniele B, Simeone E, On Behalf Of Scito Youth. BRAF Gene and Melanoma: Back to the Future. Int J Mol Sci 2021;22:3474. [PMID: 33801689 DOI: 10.3390/ijms22073474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
214 Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, Holst PJ, Bassi MR, Stornaiuolo M, Mori F, Vassilev V, Li W, Donnison T, Gentile C, Turner B, von Delft A, Del Sorbo M, Barra F, Contino AM, Abbate A, Novellino E, Thomsen AR, Christensen JP, Lahm A, Grazioli F, Ammendola V, Siani L, Colloca S, Klenerman P, Nicosia A, Dorrell L, Folgori A, Capone S, Barnes E; PEACHI Consortium. MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. Sci Transl Med 2020;12:eaaz7715. [PMID: 32554708 DOI: 10.1126/scitranslmed.aaz7715] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
215 Johnson DB, Taylor KB, Cohen JV, Ayoubi N, Haugh AM, Wang DY, Schlick BD, Voorhees AL, Gage KL, Fintelmann FJ, Sullivan RJ, Eroglu Z, Abramson RG. Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. Cancer Immunol Res 2019;7:1755-9. [PMID: 31462410 DOI: 10.1158/2326-6066.CIR-18-0717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
216 Dong X, Song J, Chen B, Qi Y, Jiang W, Li H, Zheng D, Wang Y, Zhang X, Liu H. Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. Front Oncol 2020;10:592811. [PMID: 33718105 DOI: 10.3389/fonc.2020.592811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Invest 2019;129:1407-18. [PMID: 30829653 DOI: 10.1172/JCI122287] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
218 Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM; German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer. Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. J Clin Oncol 2020;38:2543-51. [PMID: 32530760 DOI: 10.1200/JCO.19.03034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
219 Huemer F, Leisch M, Geisberger R, Zaborsky N, Greil R. miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. Pharmaceuticals (Basel) 2021;14:89. [PMID: 33530393 DOI: 10.3390/ph14020089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
220 Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med 2021;27:34-44. [PMID: 33442008 DOI: 10.1038/s41591-020-01195-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
221 Wilson MA, Zhong J, Rosenbaum BE, Utter K, Moran U, Darvishian F, Polsky D, Berman RS, Shapiro RL, Pavlick AC, Osman I. Impact of initial stage on metastatic melanoma survival. Melanoma Res 2019;29:281-8. [PMID: 31026246 DOI: 10.1097/CMR.0000000000000526] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
222 Aoki M, Iwasa S, Boku N. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer 2021;24:567-76. [PMID: 33646464 DOI: 10.1007/s10120-021-01164-x] [Reference Citation Analysis]
223 Tanaka N, Kanatani S, Kaczynska D, Fukumoto K, Louhivuori L, Mizutani T, Kopper O, Kronqvist P, Robertson S, Lindh C, Kis L, Pronk R, Niwa N, Matsumoto K, Oya M, Miyakawa A, Falk A, Hartman J, Sahlgren C, Clevers H, Uhlén P. Three-dimensional single-cell imaging for the analysis of RNA and protein expression in intact tumour biopsies. Nat Biomed Eng 2020;4:875-88. [PMID: 32601394 DOI: 10.1038/s41551-020-0576-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
224 Chang CY, Park H, Malone DC, Wang CY, Wilson DL, Yeh YM, Van Boemmel-Wegmann S, Lo-Ciganic WH. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2020;3:e201611. [PMID: 32211869 DOI: 10.1001/jamanetworkopen.2020.1611] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
225 Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med 2018;7:32. [PMID: 30294755 DOI: 10.1186/s40169-018-0210-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
226 Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol 2018;25:1814-27. [PMID: 29500764 DOI: 10.1245/s10434-018-6379-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
227 Riefolo M, Porcellini E, Dika E, Broseghini E, Ferracin M. Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Mol Oncol 2019;13:74-98. [PMID: 30499222 DOI: 10.1002/1878-0261.12412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
228 Routman DM, Garant A, Lester SC, Day CN, Harmsen WS, Sanheuza CT, Yoon HH, Neben-Wittich MA, Martenson JA, Haddock MG, Hallemeier CL, Merrell KW. A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. Adv Radiat Oncol 2019;4:63-9. [PMID: 30706012 DOI: 10.1016/j.adro.2018.09.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
229 Dimitriou F, Staeger R, Ak M, Maissen M, Kudura K, Barysch MJ, Levesque MP, Cheng PF, Dummer R, Mangana J. Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers (Basel) 2021;13:2931. [PMID: 34208218 DOI: 10.3390/cancers13122931] [Reference Citation Analysis]
230 Luke JJ. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist 2019;24:e1197-211. [PMID: 31064886 DOI: 10.1634/theoncologist.2018-0876] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
231 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Reference Citation Analysis]
232 Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Int J Mol Sci 2021;22:5123. [PMID: 34066087 DOI: 10.3390/ijms22105123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Malissen N, Grob JJ. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. Drugs 2018;78:1197-209. [PMID: 30097888 DOI: 10.1007/s40265-018-0945-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
234 Liu J, Rozeman EA, O'Donnell JS, Allen S, Fanchi L, Smyth MJ, Blank CU, Teng MWL. Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. Oncoimmunology 2019;8:e1546068. [PMID: 30713806 DOI: 10.1080/2162402X.2018.1546068] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
235 De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F. Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma. J Hematol Oncol 2018;11:68. [PMID: 29776373 DOI: 10.1186/s13045-018-0612-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
236 Luo H, Zhang T, Cheng P, Li D, Ogorodniitchouk O, Lahmamssi C, Wang G, Lan M. Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors. Oncol Lett 2020;20:2525-36. [PMID: 32782571 DOI: 10.3892/ol.2020.11858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
237 Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.J Immunother Cancer. 2019;7:106. [PMID: 30992053 DOI: 10.1186/s40425-019-0585-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 37.5] [Reference Citation Analysis]
238 Adam T, Becker TM, Chua W, Bray V, Roberts TL. The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack. Cancers (Basel) 2021;13:E277. [PMID: 33451015 DOI: 10.3390/cancers13020277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
239 Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med 2021;19:142. [PMID: 33827575 DOI: 10.1186/s12967-021-02808-3] [Reference Citation Analysis]
240 Isaksson K, Katsarelias D, Mikiver R, Carneiro A, Ny L, Olofsson Bagge R. A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. Ann Surg Oncol 2019;26:2839-45. [PMID: 31111349 DOI: 10.1245/s10434-019-07448-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
241 Christofyllakis K, Pföhler C, Bewarder M, Müller CSL, Thurner L, Rixecker T, Vogt T, Stilgenbauer S, Yordanova K, Kaddu-Mulindwa D. Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:637161. [PMID: 33680957 DOI: 10.3389/fonc.2020.637161] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimadamore A, Montironi R, Massari F. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF? Transl Androl Urol 2021;10:1581-7. [PMID: 33850792 DOI: 10.21037/tau-20-1125] [Reference Citation Analysis]
243 Han D, van Akkooi ACJ, Straker RJ 3rd, Shannon AB, Karakousis GC, Wang L, Kim KB, Reintgen D. Current management of melanoma patients with nodal metastases. Clin Exp Metastasis 2021. [PMID: 33961168 DOI: 10.1007/s10585-021-10099-7] [Reference Citation Analysis]
244 Barquet-Munoz SA, Leitao M, Pérez Montiel MD, Santiago Concha BG. Vulvar melanoma: management of primary disease and repeated recurrences. Int J Gynecol Cancer 2019;29:1077-81. [PMID: 31196869 DOI: 10.1136/ijgc-2019-000610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Nebhan CA, Johnson DB. Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. Expert Rev Anticancer Ther 2021;21:583-90. [PMID: 33504219 DOI: 10.1080/14737140.2021.1882856] [Reference Citation Analysis]
246 Ho TTB, Nasti A, Seki A, Komura T, Inui H, Kozaka T, Kitamura Y, Shiba K, Yamashita T, Yamashita T, Mizukoshi E, Kawaguchi K, Wada T, Honda M, Kaneko S, Sakai Y. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer 2020;8:e001367. [PMID: 33188035 DOI: 10.1136/jitc-2020-001367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
247 Gonzalez A. Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis. Am J Clin Dermatol 2018;19:24-30. [PMID: 30374897 DOI: 10.1007/s40257-018-0379-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
248 Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers (Basel) 2020;12:E3285. [PMID: 33172030 DOI: 10.3390/cancers12113285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
249 Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 2021;17:389-99. [PMID: 33875857 DOI: 10.1038/s41574-021-00484-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
250 Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019;8:e1524695. [PMID: 30546965 DOI: 10.1080/2162402x.2018.1524695] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
251 Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol 2021;11:670726. [PMID: 34178657 DOI: 10.3389/fonc.2021.670726] [Reference Citation Analysis]
252 Freeman M, Laks S. Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship. Melanoma Manag. 2019;6:MMT12. [PMID: 31236204 DOI: 10.2217/mmt-2019-0003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
253 Reschke R, Gussek P, Ziemer M. Identifying High-Risk Tumors within AJCC Stage IB-III Melanomas Using a Seven-Marker Immunohistochemical Signature. Cancers (Basel) 2021;13:2902. [PMID: 34200680 DOI: 10.3390/cancers13122902] [Reference Citation Analysis]
254 Nijhuis AAG, Spillane AJ, Stretch JR, Saw RPM, Menzies AM, Uren RF, Thompson JF, Nieweg OE. Current management of patients with melanoma who are found to be sentinel node-positive. ANZ J Surg 2020;90:491-6. [PMID: 31667924 DOI: 10.1111/ans.15491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
255 Tagod MSO, Mizuta S, Sakai Y, Iwasaki M, Shiraishi K, Senju H, Mukae H, Morita CT, Tanaka Y. Determination of human γδ T cell-mediated cytotoxicity using a non-radioactive assay system. J Immunol Methods 2019;466:32-40. [PMID: 30654042 DOI: 10.1016/j.jim.2019.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
256 Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res 2019;38:268. [PMID: 31217020 DOI: 10.1186/s13046-019-1266-0] [Cited by in Crossref: 164] [Cited by in F6Publishing: 134] [Article Influence: 82.0] [Reference Citation Analysis]
257 Haugh AM, Johnson DB. Management of V600E and V600K BRAF-Mutant Melanoma. Curr Treat Options Oncol 2019;20:81. [PMID: 31741065 DOI: 10.1007/s11864-019-0680-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
258 Gamboa AC, Lowe M, Yushak ML, Delman KA. Surgical Considerations and Systemic Therapy of Melanoma. Surg Clin North Am 2020;100:141-59. [PMID: 31753109 DOI: 10.1016/j.suc.2019.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
259 Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene. 2018;37:4639-4661. [PMID: 29765155 DOI: 10.1038/s41388-018-0303-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 33.7] [Reference Citation Analysis]
260 Khunger A, Piazza E, Warren S, Smith TH, Ren X, White A, Elliott N, Cesano A, Beechem JM, Kirkwood JM, Tarhini AA. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One 2021;16:e0245287. [PMID: 33428680 DOI: 10.1371/journal.pone.0245287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer 2019;7:112. [PMID: 31014385 DOI: 10.1186/s40425-019-0583-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
262 Zhao P, Qiu L, Zhou S, Li L, Qian Z, Zhang H. Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. Int J Nanomedicine 2021;16:2107-21. [PMID: 33737808 DOI: 10.2147/IJN.S295565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
263 Guo CY, Jiang SC, Kuang YK, Hu H. Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. J Cancer 2019;10:120-30. [PMID: 30662532 DOI: 10.7150/jca.28120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
264 Wada-Ohno M, Ito T, Furue M. Adjuvant Therapy for Melanoma. Curr Treat Options Oncol 2019;20:63. [PMID: 31236710 DOI: 10.1007/s11864-019-0666-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
265 Faury S, Foucaud J. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. PLoS One 2020;15:e0227344. [PMID: 31978145 DOI: 10.1371/journal.pone.0227344] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
266 Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS. Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Res 2018;28:618-28. [PMID: 30216199 DOI: 10.1097/CMR.0000000000000507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
267 Wahler S, Müller A, Koll C, Seyed-Abbaszadeh P, Von Der Schulenburg JM. Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany. J Mark Access Health Policy 2020;9:1861804. [PMID: 33456727 DOI: 10.1080/20016689.2020.1861804] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Leong SP, Wu M, Lu Y, Torre DM, von Bakonyi A, Ospina AM, Newsom JD, Luckett WS, Soon CW, Kim KB, Kashani-Sabet M. Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery. Ann Surg Oncol 2018;25:3326-33. [PMID: 30105436 DOI: 10.1245/s10434-018-6685-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
269 Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn) 2018;22:61-7. [PMID: 29628796 DOI: 10.5114/wo.2018.73889] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
270 Jia L, Zhang Q, Zhang R. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 2018;15:116-123. [PMID: 29951336 DOI: 10.20892/j.issn.2095-3941.2017.0086] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
271 Sun G, Cao Y, Qian C, Wan Z, Zhu J, Guo J, Shi L. Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages. Aging (Albany NY) 2020;12:1114-27. [PMID: 31945745 DOI: 10.18632/aging.102648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
272 Wohlmuth C, Wohlmuth-Wieser I. Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. Am J Clin Dermatol 2021;22:639-51. [PMID: 34125416 DOI: 10.1007/s40257-021-00614-7] [Reference Citation Analysis]
273 Petrella TM, Fletcher GG, Knight G, McWhirter E, Rajagopal S, Song X, Baetz TD. Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline. Curr Oncol 2020;27:e43-52. [PMID: 32218667 DOI: 10.3747/co.27.5933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
274 Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol 2020;83:1239-53. [PMID: 32461079 DOI: 10.1016/j.jaad.2020.03.131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
275 Ceci C, Atzori MG, Lacal PM, Graziani G. Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers (Basel) 2020;12:E3401. [PMID: 33212945 DOI: 10.3390/cancers12113401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
276 Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 2018;29:1861-8. [PMID: 29945191 DOI: 10.1093/annonc/mdy226] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 30.5] [Reference Citation Analysis]
277 Arora P, Talamo L, Dillon P, Gentzler RD, Millard T, Salerno M, Slingluff CL Jr, Gaughan EM. Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. Cardiooncology 2020;6:21. [PMID: 32983574 DOI: 10.1186/s40959-020-00076-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
278 Rizk EM, Gartrell RD, Barker LW, Esancy CL, Finkel GG, Bordbar DD, Saenger YM. Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy. Hematol Oncol Clin North Am 2019;33:291-9. [PMID: 30833001 DOI: 10.1016/j.hoc.2018.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
279 Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int 2020;126:73-82. [PMID: 32233107 DOI: 10.1111/bju.15058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
280 Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer 2020;8:e000398. [PMID: 32238470 DOI: 10.1136/jitc-2019-000398] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 28.0] [Reference Citation Analysis]
281 Ipenburg NA, Nieweg OE, Ahmed T, van Doorn R, Scolyer RA, Long GV, Thompson JF, Lo S. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. Br J Surg 2019;106:1319-26. [PMID: 31310333 DOI: 10.1002/bjs.11262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
282 Samuel E, Moore M, Voskoboynik M, Shackleton M, Haydon A. An update on adjuvant systemic therapies in melanoma. Melanoma Manag 2019;6:MMT28. [PMID: 31807279 DOI: 10.2217/mmt-2019-0009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
283 Garcia D, Beal JR, Alvarez DM, Macarenco RSES, Schvartsman G. Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma. Case Rep Oncol 2021;14:881-5. [PMID: 34248554 DOI: 10.1159/000516036] [Reference Citation Analysis]
284 Zhang P, Xiong X, Rolfo C, Du X, Zhang Y, Yang H, Russo A, Devenport M, Zhou P, Liu Y, Zheng P. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. Cancers (Basel) 2020;12:E284. [PMID: 31991588 DOI: 10.3390/cancers12020284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
285 Pilla L, Alberti A, Di Mauro P, Gemelli M, Cogliati V, Cazzaniga ME, Bidoli P, Maccalli C. Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Cancers (Basel) 2020;12:E3456. [PMID: 33233603 DOI: 10.3390/cancers12113456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
286 Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, Kim K, Loibner H, Gillies SD, Sondel PM. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother 2018;67:1647-58. [PMID: 30073390 DOI: 10.1007/s00262-018-2223-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
287 Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38. [PMID: 32382051 DOI: 10.1038/s41572-020-0160-6] [Cited by in Crossref: 98] [Cited by in F6Publishing: 76] [Article Influence: 98.0] [Reference Citation Analysis]
288 Cherri S, Noventa S, Fanelli M, Calandra G, Prochilo T, Bnà C, Savelli G, Zaniboni A. Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers (Basel) 2021;13:1052. [PMID: 33801385 DOI: 10.3390/cancers13051052] [Reference Citation Analysis]
289 Jansen MR, Vrielink OM, Faut M, Deckers EA, Been LB, van Leeuwen BL. One-Year Morbidity Following Videoscopic Inguinal Lymphadenectomy for Stage III Melanoma. Cancers (Basel) 2021;13:1450. [PMID: 33810068 DOI: 10.3390/cancers13061450] [Reference Citation Analysis]
290 Mowery YM, Patel K, Chowdhary M, Rushing CN, Roy Choudhury K, Lowe JR, Olson AC, Wisdom AJ, Salama JK, Hanks BA, Khan MK, Salama AKS. Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study. Radiother Oncol 2019;138:114-20. [PMID: 31252292 DOI: 10.1016/j.radonc.2019.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
291 Lanier CM, Hughes R, Ahmed T, LeCompte M, Masters AH, Petty WJ, Ruiz J, Triozzi P, Su J, O'Neill S, Watabe K, Cramer CK, Laxton AW, Tatter SB, Wang G, Whitlow C, Chan MD. Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neurooncol Pract 2019;6:402-9. [PMID: 31555455 DOI: 10.1093/nop/npz004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
292 Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int. 2019;13:248-252. [PMID: 30607787 DOI: 10.1007/s12072-018-9921-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
293 Urbani F, Ferraresi V, Capone I, Macchia I, Palermo B, Nuzzo C, Torsello A, Pezzotti P, Giannarelli D, Pozzi AF, Santaquilani M, Roazzi P, Bastucci S, Catricalà C, La Malfa A, Vercillo G, Gualtieri N, Buccione C, Castiello L, Cognetti F, Nisticò P, Belardelli F, Moschella F, Proietti E. Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Front Oncol 2020;10:202. [PMID: 32211314 DOI: 10.3389/fonc.2020.00202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
294 Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, Sundararajan S. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies (Basel) 2019;8:E51. [PMID: 31640266 DOI: 10.3390/antib8040051] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
295 Rogers SJ, Puric E, Eberle B, Datta NR, Bodis SB. Radiotherapy for Melanoma: More than DNA Damage. Dermatol Res Pract 2019;2019:9435389. [PMID: 31073304 DOI: 10.1155/2019/9435389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
296 Petrova V, Arkhypov I, Weber R, Groth C, Altevogt P, Utikal J, Umansky V. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. Int J Mol Sci 2020;21:E2367. [PMID: 32235439 DOI: 10.3390/ijms21072367] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
297 Liu H, Pan C, Song W, Liu D, Li Z, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res 2021;9:62. [PMID: 34332618 DOI: 10.1186/s40364-021-00316-6] [Reference Citation Analysis]
298 Song P, Zhang D, Cui X, Zhang L. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer 2020;11:2406-30. [PMID: 32643323 DOI: 10.1111/1759-7714.13541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
299 Ye B, Stary CM, Li X, Gao Q, Kang C, Xiong X. Engineering chimeric antigen receptor-T cells for cancer treatment. Mol Cancer 2018;17:32. [PMID: 29448937 DOI: 10.1186/s12943-018-0814-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
300 Gaiser MR, Bongiorno M, Brownell I. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Rev Clin Pharmacol. 2018;11:345-359. [PMID: 29478343 DOI: 10.1080/17512433.2018.1445966] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
301 Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. Clin Drug Investig 2020;40:629-43. [PMID: 32418051 DOI: 10.1007/s40261-020-00922-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
302 Bloemendal M, van Willigen WW, Bol KF, Boers-Sonderen MJ, Bonenkamp JJ, Werner JEM, Aarntzen EHJG, Koornstra RHT, de Groot JWB, de Vries IJM, van der Hoeven JJM, Gerritsen WR, de Wilt JHW. Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. Ann Surg Oncol 2019;26:3945-52. [PMID: 30830540 DOI: 10.1245/s10434-019-07274-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
303 Teterycz P, Ługowska I, Koseła-Paterczyk H, Rutkowski P. Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage. World J Surg Oncol 2019;17:129. [PMID: 31345228 DOI: 10.1186/s12957-019-1669-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
304 Ito S, Tachimori Y, Terado Y, Sakon R, Narita K, Goto M. Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report. J Med Case Rep 2021;15:237. [PMID: 33947459 DOI: 10.1186/s13256-021-02821-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res 2021;27:4195-204. [PMID: 33753453 DOI: 10.1158/1078-0432.CCR-20-4301] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Furue M, Ito T, Wada N, Wada M, Kadono T, Uchi H. Melanoma and Immune Checkpoint Inhibitors. Curr Oncol Rep 2018;20:29. [PMID: 29569208 DOI: 10.1007/s11912-018-0676-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
307 Barroso-Sousa R, Ott PA. Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Curr Oncol Rep 2018;21:1. [PMID: 30498900 DOI: 10.1007/s11912-018-0738-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
308 Lim KHJ, Spain L, Barker C, Georgiou A, Walls G, Gore M, Turajlic S, Board R, Larkin JM, Lorigan P. Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. ESMO Open 2018;3:e000317. [PMID: 29531842 DOI: 10.1136/esmoopen-2017-000317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
309 Davies MA, Flaherty KT. Melanoma in 2017: Moving treatments earlier to move further forwards. Nat Rev Clin Oncol 2018;15:75-6. [PMID: 29182162 DOI: 10.1038/nrclinonc.2017.183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
310 Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med 2019;17:90. [PMID: 31068190 DOI: 10.1186/s12916-019-1326-5] [Cited by in Crossref: 119] [Cited by in F6Publishing: 93] [Article Influence: 59.5] [Reference Citation Analysis]
311 Chan IS, Bhatia S, Kaufman HL, Lipson EJ. Immunotherapy for Merkel cell carcinoma: a turning point in patient care. J Immunother Cancer. 2018;6:23. [PMID: 29566749 DOI: 10.1186/s40425-018-0335-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
312 Chen D, Menon H, Verma V, Guo C, Ramapriyan R, Barsoumian H, Younes A, Hu Y, Wasley M, Cortez MA, Welsh J. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. J Immunother Cancer 2020;8:e000492. [PMID: 31996395 DOI: 10.1136/jitc-2019-000492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
313 Moran A, Azghadi S, Maverakis EM, Christensen S, Dyer BA. Combined Immune Checkpoint Blockade and Stereotactic Ablative Radiotherapy Can Stimulate Response to Immunotherapy in Metastatic Melanoma: A Case Report. Cureus 2019;11:e4038. [PMID: 31011500 DOI: 10.7759/cureus.4038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
314 Vreeland TJ, Clifton GT, Hale DF, Chick RC, Hickerson AT, Cindass JL, Adams AM, Bohan PMK, Andtbacka RHI, Berger AC, Jakub JW, Sussman JJ, Terando AM, Wagner T, Peoples GE, Faries MB. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis. Ann Surg Oncol 2021. [PMID: 33641012 DOI: 10.1245/s10434-021-09709-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Reschke R, Gussek P, Boldt A, Sack U, Köhl U, Lordick F, Gora T, Kreuz M, Reiche K, Simon JC, Ziemer M, Kunz M. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. Int J Mol Sci 2021;22:8017. [PMID: 34360781 DOI: 10.3390/ijms22158017] [Reference Citation Analysis]
316 Liao Y, Han P, Zhang Y, Ni B. Physio-pathological effects of m6A modification and its potential contribution to melanoma. Clin Transl Oncol 2021. [PMID: 34105069 DOI: 10.1007/s12094-021-02644-3] [Reference Citation Analysis]
317 Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931. [PMID: 33193345 DOI: 10.3389/fimmu.2020.568931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
318 Kohoutova D, Worku D, Aziz H, Teare J, Weir J, Larkin J. Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. Cells 2021;10:327. [PMID: 33562484 DOI: 10.3390/cells10020327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Monti M, Consoli F, Vescovi R, Bugatti M, Vermi W. Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. Cells 2020;9:E417. [PMID: 32054102 DOI: 10.3390/cells9020417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
320 Weiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: Facts and Hopes. Clin Cancer Res 2019;25:5191-201. [PMID: 30923036 DOI: 10.1158/1078-0432.CCR-18-1550] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 32.5] [Reference Citation Analysis]
321 Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. Br J Cancer 2021;124:574-80. [PMID: 33087895 DOI: 10.1038/s41416-020-01121-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
322 Onesti CE, Frères P, Jerusalem G. Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment. J Thorac Dis 2019;11:35-8. [PMID: 30863564 DOI: 10.21037/jtd.2018.12.47] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
323 Jansen YJL, Willekens I, Seremet T, Awada G, Schwarze JK, De Mey J, Brussaard C, Neyns B. Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. Cancers (Basel) 2021;13:442. [PMID: 33503861 DOI: 10.3390/cancers13030442] [Reference Citation Analysis]
324 Pelster MS, Amaria RN. Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Curr Treat Options Oncol 2020;21:10. [PMID: 32025932 DOI: 10.1007/s11864-020-0700-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
325 Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, Papaliodis GN, Kodati S, Bishop R, Magone MT, Sobrin L, Sen HN. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. Ocul Immunol Inflamm 2020;28:854-9. [PMID: 31013173 DOI: 10.1080/09273948.2019.1583347] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
326 Shan Q, Lu H. Immune Checkpoint Inhibitors in Special Populations. Technol Cancer Res Treat 2021;20:15330338211036526. [PMID: 34384286 DOI: 10.1177/15330338211036526] [Reference Citation Analysis]
327 Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 2020;38:1429-41. [PMID: 31990608 DOI: 10.1200/JCO.19.01508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
328 Ardolino L, Joshua A. Immune checkpoint inhibitors in malignancy. Aust Prescr 2019;42:62-7. [PMID: 31048940 DOI: 10.18773/austprescr.2019.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
329 Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
330 Gallo M, Guarnotta V, De Cicco F, Rubino M, Faggiano A, Colao A; NIKE Group. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. J Cancer Res Clin Oncol 2019;145:429-43. [PMID: 30617553 DOI: 10.1007/s00432-019-02839-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
331 Lu S, Sun Z, Hu W, Yin S, Zhao C, Hu H. PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B. Cancer Sci 2021;112:1878-87. [PMID: 33583114 DOI: 10.1111/cas.14844] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
332 Buchwald ZS, Nasti TH, Lee J, Eberhardt CS, Wieland A, Im SJ, Lawson D, Curran W, Ahmed R, Khan MK. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J Immunother Cancer 2020;8:e000867. [PMID: 33028691 DOI: 10.1136/jitc-2020-000867] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
333 Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 2019;25:100420. [PMID: 31517036 DOI: 10.1016/j.ijcha.2019.100420] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
334 Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel) 2021;13:1383. [PMID: 33803762 DOI: 10.3390/cancers13061383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Masoud SJ, Perone JA, Farrow NE, Mosca PJ, Tyler DS, Beasley GM. Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. Curr Treat Options Oncol 2018;19:55. [PMID: 30232648 DOI: 10.1007/s11864-018-0575-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
336 Seidl S, Schuster B, Rüth M, Biedermann T, Zink A. What Do Germans Want to Know About Skin Cancer? A Nationwide Google Search Analysis From 2013 to 2017. J Med Internet Res 2018;20:e10327. [PMID: 29698213 DOI: 10.2196/10327] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
337 Wang X, Kong Y, Chi Z, Sheng X, Cui C, Mao L, Lian B, Tang B, Yan X, Si L, Guo J. Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. Thorac Cancer. 2019;10:950-956. [PMID: 30864295 DOI: 10.1111/1759-7714.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
338 Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J 2019;42:299-306. [PMID: 31783990 DOI: 10.1016/j.bj.2019.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
339 Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, Fuse N, Kuboki Y, Shimizu T, Yamamoto N, Nishio K, Kawakami Y, Nihira SI, Sase K, Nonaka T, Takahashi H, Komori Y, Kiyohara K. Guidelines for clinical evaluation of anti-cancer drugs. Cancer Sci 2021;112:2563-77. [PMID: 33990993 DOI: 10.1111/cas.14967] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
340 Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G, Richtig M, Grübler MR, Gappmayer A, Haidn T, Kofler J, Huegel R, Lange-Asschenfeldt B, Pichler M, Pilz S, Heinemann A, Richtig E. Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. PLoS One 2018;13:e0204729. [PMID: 30273398 DOI: 10.1371/journal.pone.0204729] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
341 Heitmann JS, Walz JS, Pflügler M, Kauer J, Schlenk RF, Jung G, Salih HR. Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. BMJ Open 2020;10:e039639. [PMID: 33067297 DOI: 10.1136/bmjopen-2020-039639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
342 Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018;175:313-326. [PMID: 30290139 DOI: 10.1016/j.cell.2018.09.035] [Cited by in Crossref: 390] [Cited by in F6Publishing: 335] [Article Influence: 195.0] [Reference Citation Analysis]
343 Li M, Liu D, Lee D, Kapoor S, Gibson-Corley KN, Quinn TP, Sagastume EA, Mott SL, Walsh SA, Acevedo MR, Johnson FL, Schultz MK. Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma. Mol Pharm 2019;16:3904-15. [PMID: 31318566 DOI: 10.1021/acs.molpharmaceut.9b00512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
344 Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA. Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer 2020;8:e000948. [PMID: 33037115 DOI: 10.1136/jitc-2020-000948] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
345 Verver D, van Klaveren D, Franke V, van Akkooi ACJ, Rutkowski P, Keilholz U, Eggermont AMM, Nijsten T, Grünhagen DJ, Verhoef C. Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes. Br J Surg 2019;106:217-25. [PMID: 30307046 DOI: 10.1002/bjs.10995] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
346 Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med 2020;18:346. [PMID: 32894202 DOI: 10.1186/s12967-020-02482-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 van Holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. Drugs Aging 2019;36:927-38. [PMID: 31317421 DOI: 10.1007/s40266-019-00697-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 31.0] [Reference Citation Analysis]
348 Alves Costa Silva C, Facchinetti F, Routy B, Derosa L. New pathways in immune stimulation: targeting OX40. ESMO Open 2020;5:e000573. [PMID: 32392177 DOI: 10.1136/esmoopen-2019-000573] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
349 Perone JA, Farrow N, Tyler DS, Beasley GM. Contemporary Approaches to In-Transit Melanoma. J Oncol Pract 2018;14:292-300. [PMID: 29746804 DOI: 10.1200/JOP.18.00063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
350 Rotman J, Koster BD, Jordanova ES, Heeren AM, de Gruijl TD. Unlocking the therapeutic potential of primary tumor-draining lymph nodes. Cancer Immunol Immunother 2019;68:1681-8. [PMID: 30944963 DOI: 10.1007/s00262-019-02330-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
351 Ankeny JS, Labadie B, Luke J, Hsueh E, Messina J, Zager JS. Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clin Exp Metastasis 2018;35:487-93. [PMID: 29722000 DOI: 10.1007/s10585-018-9892-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
352 Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer 2018;6:112. [PMID: 30352626 DOI: 10.1186/s40425-018-0428-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
353 Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 2019;26:G1-G18. [PMID: 30400055 DOI: 10.1530/ERC-18-0320] [Cited by in Crossref: 49] [Cited by in F6Publishing: 14] [Article Influence: 49.0] [Reference Citation Analysis]
354 da Veiga CRP, da Veiga CP, Souza A, Wainstein AJA, de Melo AC, Drummond-Lage AP. Cutaneous melanoma: cost of illness under Brazilian health system perspectives. BMC Health Serv Res 2021;21:284. [PMID: 33781270 DOI: 10.1186/s12913-021-06246-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 van Willigen WW, Bloemendal M, Boers-Sonderen MJ, de Groot JWB, Koornstra RHT, van der Veldt AAM, Haanen JBAG, Boudewijns S, Schreibelt G, Gerritsen WR, de Vries IJM, Bol KF. Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. Oncoimmunology 2020;9:1738814. [PMID: 33457087 DOI: 10.1080/2162402X.2020.1738814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
356 Beielstein AC, Pallasch CP. Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy. Int J Mol Sci 2019;20:E4158. [PMID: 31454887 DOI: 10.3390/ijms20174158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
357 Hijikata Y, Matsubara Y, Ota Y, Lim LA, Tani K, Hirata Y, Yotsuyanagi H. Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. Intern Med 2020;59:1105-9. [PMID: 32009094 DOI: 10.2169/internalmedicine.3901-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
358 Hanks JE, Kovatch KJ, Ali SA, Roberts E, Durham AB, Smith JD, Bradford CR, Malloy KM, Boonstra PS, Lao CD, McLean SA. Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety. Otolaryngol Head Neck Surg 2020;162:520-9. [PMID: 32041486 DOI: 10.1177/0194599819899934] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
359 Indini A, Grossi F, Mandalà M, Taverna D, Audrito V. Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. Biomedicines 2021;9:607. [PMID: 34073463 DOI: 10.3390/biomedicines9060607] [Reference Citation Analysis]
360 Pampena MB, Cartar HC, Cueto GR, Levy EM, Blanco PA, Barrio MM, Mordoh J. Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants. Front Immunol 2018;9:2531. [PMID: 30450100 DOI: 10.3389/fimmu.2018.02531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
361 Sheikh AR, Yameen H, Hartshorn K. Treatment of Rectal Cancer in Older Adults. Curr Oncol Rep. 2018;20:102. [PMID: 30456634 DOI: 10.1007/s11912-018-0746-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
362 Ipenburg NA, Thompson JF, Uren RF, Chung D, Nieweg OE. Focused Ultrasound Surveillance of Lymph Nodes Following Lymphoscintigraphy Without Sentinel Node Biopsy: A Useful and Safe Strategy in Elderly or Frail Melanoma Patients. Ann Surg Oncol 2019;26:2855-63. [PMID: 31240588 DOI: 10.1245/s10434-019-07505-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
363 Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gérard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst BA, Saenger YM. Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma. Clin Cancer Res 2019;25:2494-502. [PMID: 30647081 DOI: 10.1158/1078-0432.CCR-18-2847] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
364 Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. J Natl Cancer Inst 2019;111:719-26. [PMID: 30551196 DOI: 10.1093/jnci/djy193] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 34.0] [Reference Citation Analysis]
365 Malnick SDH, Abdullah A, Neuman MG. Checkpoint Inhibitors and Hepatotoxicity. Biomedicines 2021;9:101. [PMID: 33494227 DOI: 10.3390/biomedicines9020101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
366 Meraz-Muñoz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C, Kim J, Wald R, Kitchlu A. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 2020;8:e000467. [PMID: 32601079 DOI: 10.1136/jitc-2019-000467] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
367 Boada A, Carrera C, Segura S, Collgros H, Pasquali P, Bodet D, Puig S, Malvehy J. Cutaneous toxicities of new treatments for melanoma. Clin Transl Oncol 2018;20:1373-84. [PMID: 29799097 DOI: 10.1007/s12094-018-1891-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
368 Ebia MI, Capone S, Ricker C, Thomas JS, Tulpule V, Kang I, D'Souza A, Freyer DR, Miller K, In GK. A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma. Cureus 2021;13:e15480. [PMID: 34262818 DOI: 10.7759/cureus.15480] [Reference Citation Analysis]
369 Falk Delgado A, Zommorodi S, Falk Delgado A. Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma. Curr Oncol Rep 2019;21:54. [PMID: 31028497 DOI: 10.1007/s11912-019-0798-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
370 Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Manag 2019;6:MMT33. [PMID: 31871622 DOI: 10.2217/mmt-2019-0015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
371 Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367. [PMID: 32001626 DOI: 10.1126/science.aax0182] [Cited by in Crossref: 137] [Cited by in F6Publishing: 107] [Article Influence: 137.0] [Reference Citation Analysis]
372 Standage H, Hersh AR, Caughey A, Taylor M, Vetto J, Han D. What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node? Ann Surg Oncol 2021;28:2913-22. [PMID: 32951110 DOI: 10.1245/s10434-020-09137-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
373 Song J, Jin C, Chen E, Dong X, Zhu L. L Antigen Family Member 3 Serves as a Prognostic Biomarker for the Clinical Outcome and Immune Infiltration in Skin Cutaneous Melanoma. Biomed Res Int 2021;2021:6648182. [PMID: 33829062 DOI: 10.1155/2021/6648182] [Reference Citation Analysis]
374 Jiang X, Li L, Li Y, Li Q. Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. J Cancer 2019;10:1764-71. [PMID: 31205532 DOI: 10.7150/jca.26481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
375 Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr Treat Options Oncol 2019;20:7. [PMID: 30675668 DOI: 10.1007/s11864-019-0607-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
376 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 116] [Cited by in F6Publishing: 105] [Article Influence: 29.0] [Reference Citation Analysis]
377 Adler NR, Wolfe R, McArthur GA, Kelly JW, Haydon A, McLean CA, Mar VJ. Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. Br J Cancer 2018;118:1289-95. [PMID: 29755118 DOI: 10.1038/s41416-018-0088-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
378 Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72:320-341. [PMID: 31954495 DOI: 10.1016/j.jhep.2019.10.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 40.0] [Reference Citation Analysis]
379 Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol 2020;38:567-75. [PMID: 31880964 DOI: 10.1200/JCO.19.01381] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 17.5] [Reference Citation Analysis]
380 Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D, Grimaldi AM, Pinto A, Ascierto PA. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med 2017;15:244. [PMID: 29202855 DOI: 10.1186/s12967-017-1348-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
381 Marron TU, Ryan AE, Reddy SM, Kaczanowska S, Younis RH, Thakkar D, Zhang J, Bartkowiak T, Howard R, Anderson KG, Olson D, Naqash AR, Patel RB, Sachdev E, Rodriguez-Ruiz ME, Sheffer M, Church S, Fuhrman C, Overacre-Delgoffe A, Nguyen R, Florou V, Thaxton JE, Aggen DH, Guerriero JL. Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer 2021;9:e001901. [PMID: 33653801 DOI: 10.1136/jitc-2020-001901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
382 Li X, Cai Y. Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients. Aging (Albany NY) 2020;12:16457-75. [PMID: 32858528 DOI: 10.18632/aging.103734] [Reference Citation Analysis]
383 Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, Zheng P, Liu Y. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res 2019;29:609-27. [PMID: 31267017 DOI: 10.1038/s41422-019-0184-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 14.5] [Reference Citation Analysis]
384 Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer 2018;6:44. [PMID: 29848375 DOI: 10.1186/s40425-018-0362-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
385 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
386 Indini A, Roila F, Grossi F, Massi D, Mandalà M. Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? Am J Clin Dermatol 2021;22:511-22. [PMID: 34036489 DOI: 10.1007/s40257-021-00608-5] [Reference Citation Analysis]
387 Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 2020;26:475-84. [PMID: 32273608 DOI: 10.1038/s41591-020-0829-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
388 Wohlmuth C, Wohlmuth-Wieser I. Vulvar malignancies: an interdisciplinary perspective. J Dtsch Dermatol Ges 2019;17:1257-76. [PMID: 31829526 DOI: 10.1111/ddg.13995] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
389 Song Y, Straker RJ 3rd, Xu X, Elder DE, Gimotty PA, Huang AC, Mitchell TC, Amaravadi RK, Schuchter LM, Karakousis GC. Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. Ann Surg Oncol 2020;27:2915-26. [PMID: 31898103 DOI: 10.1245/s10434-019-08174-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
390 Liu J, O'Donnell JS, Yan J, Madore J, Allen S, Smyth MJ, Teng MWL. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology 2019;8:e1581530. [PMID: 31069141 DOI: 10.1080/2162402X.2019.1581530] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
391 Farrow NE, Turner MC, Salama AKS, Beasley GM. Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis. Oncol Ther 2020;8:261-75. [PMID: 32700043 DOI: 10.1007/s40487-020-00117-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
392 Dzobo K, Senthebane DA, Ganz C, Thomford NE, Wonkam A, Dandara C. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells 2020;9:E1896. [PMID: 32823711 DOI: 10.3390/cells9081896] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
393 Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226. [PMID: 30409774 DOI: 10.1136/bmj.k4226] [Cited by in Crossref: 124] [Cited by in F6Publishing: 103] [Article Influence: 41.3] [Reference Citation Analysis]
394 Dudani P, Senthilnathan G, Wajid MA, Gupta AK, Kaushal S, Arora S, Shamim SA, Bhari N. Melanoma arising in a giant congenital melanocytic nevus with neuroblastoma RAS mutation. Indian J Dermatol Venereol Leprol 2021;87:416-20. [PMID: 33871206 DOI: 10.25259/IJDVL_591_19] [Reference Citation Analysis]